AI Peptide Design, Explained
AI peptide design turns a plain-English research goal into novel candidate sequences in under a minute. Here is how it works, what the scores mean, and where it fits in a research workflow.
What is AI peptide design?
AI peptide design uses a language model trained on peptide chemistry to propose new amino-acid sequences that fit a described research goal. Instead of searching a catalogue, you describe what you want to study in plain English and the model generates candidate sequences built for that target.
Velox Design Lab is the first tool of its kind aimed at research-peptide workflows: describe a target, get three novel candidates, each scored and novelty-checked, in under a minute.
From plain English to a scored candidate
You do not need notation or a chemistry background. You type something like "a GLP-1, GIP and glucagon triple agonist optimised for synthesisability", and the tool interprets that into a structured brief, then proposes sequences.
Each candidate is scored on synthesisability, novelty and length-optimisation, and labelled as likely-novel, partially similar, or already-existing. You can read more on what makes a peptide novel.
Where AI design fits in a research workflow
AI design is an idea-generation step. The outputs are computational hypotheses — proposals for in-vitro evaluation, not validated compounds. They give a researcher a structured starting point and a spread of distinct candidates rather than a single guess.
When a research target overlaps a well-characterised compound, it is usually faster to study the known material directly. For metabolic and incretin research, for example, that often means retatrutide; for tissue-repair work, recovery compounds such as BPC-157 and TB-500.
What it is not
AI peptide design does not produce medicines and makes no health, medical or dosing claims. Generated sequences have not been synthesised, tested, or evaluated by any regulator. Everything is supplied strictly for in vitro research by qualified researchers.
